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The kidney is both a cause and a victim of 
hypertension. High blood pressure is a key 
pathogenetic factor that contributes to deterio-
ration of kidney function. The presence of kid-
ney disease is a common and underappreciated 
preexisting medical cause of resistant hyper-
tension.1 Therefore, treatment of hypertension 
has become the most important intervention in 
the management of all forms of chronic kidney 
disease (CKD). For this reason, the forthcom-
ing World Kidney Day (WKD) on 12 March 
2009 will emphasize the role of hypertension 
in renal disease.
How does one recognize the presence  
of chronic kidney disease?
In contrast to a decade ago, today most laborato-
ries around the world report estimated glomeru-
lar filtration rate (eGFR) instead of or in addition 
to serum creatinine. This now provides the 
physician with data about kidney function that 
are, in general, more informative. As a result, a 
greater percentage of patients with diabetes or 
hypertension and their physicians have a better 
knowledge of their kidney function. Assessment 
of eGFR as an index of kidney function should 
be complemented by assessment of urine for 
protein or, preferably, albumin.
In spite of these laboratory updates, recent 
data demonstrate that a given patient’s knowl-
edge that he or she has CKD is very low. In a 
recent analysis of almost half a million people 
in Taiwan who took part in a standard medical 
screening program, 12% had CKD.2 It is note-
worthy that less than 4% of those with CKD 
were aware of their condition. People with 
CKD are several times more likely to die from 
cardiovascular causes than those without CKD; 
hypertension is a major risk factor in this con-
text.3 The combination of CKD and hyperten-
sion, therefore, is a major public-health issue; 
because of the costly treatments necessary for 
end-stage renal disease (ESRD), end-stage CKD 
has also become a substantial burden to health 
budgets.
What is the worldwide frequency  
of chronic kidney disease?
The frequency of CKD continues to increase 
worldwide, as does the prevalence of ESRD.4,5 
The most common, but not the only, causes of 
CKD are hypertension and diabetes. The pres-
ence of CKD is associated with a large increase 
in cardiovascular risk. Moreover, cardiovascu-
lar risk increases proportionally as eGFR falls 
below 60 ml/min. As a result, the identification 
and reduction of CKD has become a public-
health priority.6
The reported prevalence of CKD stages 1–4 in 
the most recent National Health and Nutrition 
Examination Survey (NHANES) between 1999 
and 2006 was 26 million out of a population base 
of approximately 200 million. This represented 
United States residents aged 20 and older; of these, 
65.3% had CKD stage 3 or 4. Those with diabe-
tes and hypertension had a far greater prevalence 
of CKD (37% and 26%, respectively) compared 
with those without these conditions (11% and 
8%, respectively).7 In a more recent, yet-unpub-
lished report from the CKD surveillance group, 
the prevalence of CKD stages 1–4 in the general 
population increased 30% from 1994 to 2006.
The most recent report of the United States 
Renal Data System estimates that nearly one-half 
million patients in the United States were treated 
for ESRD in the year 2004,8 and by 2010 this fig-
ure is expected to increase by approximately 40%. 
Patients destined to progress to ESRD—that is, 
the elderly—are a growing segment of the popula-
tion. Additionally, males and African Americans 
with preexisting hypertension and CKD are also 
at much higher risk for ESRD.9 This observation 
has also been confirmed throughout the devel-
oped world: Europe, Asia, Australia, and regions 
of India and Africa.4,5
The role of hypertension
Hypertension is a global problem, and the situ-
ation is projected to get worse. It is the major 
risk factor for development and progression in 
nondiabetic and diabetic CKD.
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The world population is getting older, and 
aging is the most common risk factor for the 
development of hypertension and diabetes as well 
as CKD. Nearly one billion people worldwide 
have high blood pressure (defined as >140/90 
mm Hg), and that number is expected to increase 
to 1.56 billion people by 2025.10 The prevalence 
of hypertension is predicted to increase by 24% 
in developed countries and by 80% in developing 
regions such as Africa and Latin America. One 
report noted that 333 million adults in economi-
cally developed regions such as North America 
and Europe had high blood pressure in 2000, and 
an additional 639 million people in developing 
countries have this condition.
In 1999–2006, the prevalence of hypertension, 
defined as >140/90 mm Hg, in US adults was 
43.4%, and similar figures have been reported 
from many Western countries.9 The rates of 
hypertension were highest in participants who 
were 60 years or older—that is 68%, versus 25% 
in those between 20 and 39 years—and in non-
Hispanic blacks—53%, versus 43% in whites 
and 34% in Mexican Americans. Furthermore, 
hypertension was more common in individu-
als with a higher body mass index (BMI) (60% 
for BMI ≥35 versus 32% for BMI of 23). Slightly 
more than half of adults with hypertension were 
aware of their disease in 1999–2004; fewer than 
half were treated for their hypertension with 
medications; and less than two-thirds were con-
trolled to <140/90 mm Hg with medication.9 This 
trend in poor blood pressure control is observed 
worldwide.
The hypertension control rate is substantially 
lower in patients with CKD, particularly among 
those with diabetes and CKD.1,9 This is illustrated 
by the US National Kidney Foundation’s Kidney 
Early Evaluation Program (KEEP), a US-based 
health-screening program for individuals at high 
risk for kidney disease.9 The prevalence (86.2%), 
awareness (80.2%), and treatment (70.0%) of 
hypertension in the screened cohort were high; 
however, blood pressure control rates were low 
(13.2%). The proportion of hypertensive patients 
increased with advancing stages of CKD.
Which blood pressure component is most relevant 
for renal and cardiovascular risk, systolic or diastolic?
There is now consensus, based on the totality of 
the data, that systolic rather than diastolic blood 
pressure poses the greater risk for cardiovascular 
events and kidney disease progression. Against 
this background, it is relevant that in the KEEP 
study, elevated systolic blood pressure accounted 
for the majority of patients with inadequate 
control. Male gender, non-Hispanic black race, 
and BMI of 30 kg/m2 or more were inversely 
related to blood pressure control.
What is the blood pressure target for CKD 
patients? According to the different guidelines 
published by the major kidney societies, systolic 
blood pressure should be lowered to values less 
than 130 mm Hg. One has to be aware, however, 
that as a predictor of adverse CKD or cardio-
vascular events, office blood pressure may be 
inferior compared with ambulatory blood pres-
sure.11 This issue is particularly relevant in CKD 
because of the tendency for nighttime blood 
pressure to be elevated (little or no nocturnal 
dip in blood pressure) and the fact that cen-
tral (aortic) blood pressure tends to be higher 
than peripheral (brachial) blood pressure.11,12 
In patients with diabetes, guidelines all recom-
mend that lower blood pressure targets may 
provide further benefit, but prospective trials 
have thus far failed to confirm this epidemio-
logical observation.
The role of diabetic nephropathy
As is indicated above, diabetes and hypertension 
are the most common causes of CKD. There are 
currently over 240 million people with diabetes 
worldwide. This figure is projected to rise to 380 
million by 2025, largely because of population 
growth, aging, urbanization, unhealthy eating 
habits, increased body fat, and a sedentary life-
style. By 2025, the number of people with diabe-
tes is expected to more than double in Southeast 
Asia, the Eastern Mediterranean and Middle East, 
and Africa. It is projected to rise by nearly 20% 
in Europe, 50% in North America, 85% in South 
and Central America, and 75% in the Western 
Pacific region. The five countries with the highest 
prevalence of diabetes, in order, are India, China, 
the United States, Russia, and Japan. Worldwide, 
more than 50% of people with diabetes are una-
ware of their condition and are not treated.
The same factors that increase obesity are 
those predisposing to diabetes: family history, 
presence of hypertension, aging, excess body 
weight, lack of exercise, and unhealthy dietary 
habits. It is important to identify these risks early 
to reduce the development of diabetes and CKD, 
since CKD greatly amplifies the risk of cardio-
vascular events in the diabetic patient.
The remaining challenge
Underdiagnosis and undertreatment of CKD are 
a worldwide problem: not only is CKD awareness 
low worldwide, but the relative lack of awareness 
of CKD risk factors—that is, hypertension and 
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diabetes—among physicians is even more dis-
turbing. Moreover, even awareness of these risk 
factors does not ensure adequate treatment; this 
could relate to the behavior of the patient, the pro-
vider, or both. Thus, the problem of CKD remains 
a challenge, as exemplified by recent data showing 
that between 1999 and 2006, less than 5% of peo-
ple with an eGFR less than 60 ml/min/1.73 m2 and 
proteinuria were aware of having CKD; of those 
with CKD stage 3, awareness was only 7.5%; for 
stage 4, awareness was less than 50%. Awareness 
rates among those with CKD stage 3 or 4 were 
higher if comorbid diagnoses of diabetes and 
hypertension were present, but even then, they 
were quite low (20% and 12%, respectively).
One barrier to overcome in order to ensure 
greater awareness is a more focused education of 
physicians, as they are in charge of the patients’ 
medical condition. In one survey, more than one-
third of primary care physicians in the United 
States were not aware that family history was a 
risk factor for CKD, and almost one-quarter did 
not perceive African-American ethnicity as a CKD 
risk factor; in contrast, nearly all perceived diabetes 
(95%) and hypertension (97%) as risk factors for 
CKD. Even more problematic was the finding that 
although diabetes and hypertension were acknowl-
edged as CKD risk factors, the achieved control 
rates (defined as reaching guideline goals), sadly, 
remained well below 50% among those treated.
What can be done about this problem?
There have been many consensus panels over the 
past decade to approach ways to achieve better 
blood pressure control and educate physicians 
to the stages of CKD.13,14 The road to improve-
ment of outcomes is to focus on public awareness 
and screening programs as well as programs to 
educate both patients and physicians. Data from 
the KEEP screening program in the United States 
have also shown that blood pressure values are 
most likely to be at goal once a patient is aware 
he or she has kidney disease.15 Data from Bolivia 
highlight the observation that once kidney dis-
ease is diagnosed, more appropriate interventions 
to reduce CKD risk factors such as hypertension 
are instituted.13
Programs to address these issues have started 
around the world, including KEEP-type programs. 
As a major focus of World Kidney Day this year, 
the issue is hypertension in CKD (http://www.
worldkidneyday.org).
Because of the aging world population and con-
sequently increasing prevalence of hypertension 
and diabetes, CKD rates will continue to increase. 
This has placed and will continue to place an undue 
economic burden on societies, given the costs of an 
ESRD program. In 2005, the United States spent 
$32 billion on such programs. These facts man-
date that measures be put forth to ensure timely 
detection and prevention of CKD progression. The 
keys to ensuring successful prevention of CKD are 
screening for hypertension, improved testing and 
diagnosis of predisposing comorbidities such as 
diabetes, and aggressive treatment to guideline 
goals.
The International Society of Nephrology and the 
International Federation of Kidney Foundations 
have an ambitious long-term goal that, worldwide, 
every individual, particularly the patient with dia-
betes, know his or her blood pressure values. Addi-
tionally, he or she should be aware that prompt 
treatment is necessary once blood pressure values 
are no longer in the normal range. Finally, our 
societies must strongly encourage public-health 
authorities to support efforts to raise public aware-
ness of CKD and promote moves to reduce the risk 
of developing hypertension. Such governmental 
public-health initiatives to reduce salt in the diet 
or to mandate that labels give sodium content are 
illustrated by the activities in the United Kingdom, 
Finland, and Japan. These initiatives have proven 
highly successful on the basis of reduction in car-
diovascular mortality and morbidity.
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